Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2012

01.10.2012 | Preclinical Study

Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery

verfasst von: Cynthia L. Miller, Michelle C. Specht, Melissa N. Skolny, Lauren S. Jammallo, Nora Horick, Jean O’Toole, Suzanne B. Coopey, Kevin Hughes, Michele Gadd, Barbara L. Smith, Alphonse G. Taghian

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Women diagnosed with or at high risk for breast cancer increasingly choose prophylactic mastectomy. It is unknown if adding sentinel lymph node biopsy (SLNB) to prophylactic mastectomy increases the risk of lymphedema. We sought to determine the risk of lymphedema after mastectomy with and without nodal evaluation. 117 patients who underwent bilateral mastectomy were prospectively screened for lymphedema. Perometer arm measurements were used to calculate weight-adjusted arm volume change at each follow-up. Of 234 mastectomies performed, 15.8 % (37/234) had no axillary surgery, 63.7 % (149/234) had SLNB, and 20.5 % (48/234) had axillary lymph node dissection (ALND). 88.0 % (103/117) of patients completed the LEFT-BC questionnaire evaluating symptoms associated with lymphedema. Multivariate analysis was used to assess clinical characteristics associated with increased weight-adjusted arm volume and patient-reported lymphedema symptoms. SLNB at the time of mastectomy did not result in an increased mean weight-adjusted arm volume compared to mastectomy without axillary surgery (p = 0.76). Mastectomy with ALND was associated with a significantly greater mean weight-adjusted arm volume change compared to mastectomy with SLNB (p < 0.0001) and without axillary surgery (p = 0.0028). Patients who underwent mastectomy with ALND more commonly reported symptoms associated with lymphedema compared to those with SLNB or no axillary surgery (p < 0.0001). Patients who underwent mastectomy with SLNB or no axillary surgery reported similar lymphedema symptoms. Addition of SLNB to mastectomy is not associated with a significant increase in measured or self-reported lymphedema rates. Therefore, SLNB may be performed at the time of prophylactic mastectomy without an increased risk of lymphedema.
Literatur
2.
Zurück zum Zitat Tuttle TM, Jarosek S, Habermann EB, Arrington A, Abraham A, Morris TJ, Virnig BA (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27(9):1362–1367. doi:10.1200/JCO.2008.20.1681 PubMedCrossRef Tuttle TM, Jarosek S, Habermann EB, Arrington A, Abraham A, Morris TJ, Virnig BA (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27(9):1362–1367. doi:10.​1200/​JCO.​2008.​20.​1681 PubMedCrossRef
3.
Zurück zum Zitat Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203–5209. doi:10.1200/JCO.2007.12.3141 PubMedCrossRef Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203–5209. doi:10.​1200/​JCO.​2007.​12.​3141 PubMedCrossRef
4.
Zurück zum Zitat McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19(19):3938–3943PubMed McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19(19):3938–3943PubMed
5.
Zurück zum Zitat Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23(19):4275–4286. doi:10.1200/JCO.2005.10.080 PubMedCrossRef Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23(19):4275–4286. doi:10.​1200/​JCO.​2005.​10.​080 PubMedCrossRef
6.
Zurück zum Zitat Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998–2007. Ann Surg Oncol 17(10):2554–2562. doi:10.1245/s10434-010-1091-3 PubMedCrossRef Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998–2007. Ann Surg Oncol 17(10):2554–2562. doi:10.​1245/​s10434-010-1091-3 PubMedCrossRef
8.
Zurück zum Zitat Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I (2006) Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107(7):1440–1447. doi:10.1002/cncr.22176 PubMedCrossRef Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I (2006) Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107(7):1440–1447. doi:10.​1002/​cncr.​22176 PubMedCrossRef
9.
Zurück zum Zitat Dupont EL, Kuhn MA, McCann C, Salud C, Spanton JL, Cox CE (2000) The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg 180(4):274–277PubMedCrossRef Dupont EL, Kuhn MA, McCann C, Salud C, Spanton JL, Cox CE (2000) The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg 180(4):274–277PubMedCrossRef
10.
Zurück zum Zitat McLaughlin SA, Stempel M, Morris EA, Liberman L, King TA (2008) Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer 112(6):1214–1221. doi:10.1002/cncr.23298 PubMedCrossRef McLaughlin SA, Stempel M, Morris EA, Liberman L, King TA (2008) Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer 112(6):1214–1221. doi:10.​1002/​cncr.​23298 PubMedCrossRef
11.
Zurück zum Zitat Laronga C, Lee MC, McGuire KP, Meade T, Carter WB, Hoover S, Cox CE (2009) Indications for sentinel lymph node biopsy in the setting of prophylactic mastectomy. J Am Coll Surg 209(6):746–752; quiz 800–741. doi:10.1016/j.jamcollsurg.2009.08.010 Laronga C, Lee MC, McGuire KP, Meade T, Carter WB, Hoover S, Cox CE (2009) Indications for sentinel lymph node biopsy in the setting of prophylactic mastectomy. J Am Coll Surg 209(6):746–752; quiz 800–741. doi:10.​1016/​j.​jamcollsurg.​2009.​08.​010
12.
Zurück zum Zitat Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE II, Giuliano AE (2006) Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13(4):491–500. doi:10.1245/ASO.2006.05.013 PubMedCrossRef Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE II, Giuliano AE (2006) Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13(4):491–500. doi:10.​1245/​ASO.​2006.​05.​013 PubMedCrossRef
13.
Zurück zum Zitat Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25(24):3657–3663. doi:10.1200/JCO.2006.07.4062 PubMedCrossRef Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25(24):3657–3663. doi:10.​1200/​JCO.​2006.​07.​4062 PubMedCrossRef
14.
Zurück zum Zitat McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol. doi:10.1200/JCO.2008.16.3766 McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol. doi:10.​1200/​JCO.​2008.​16.​3766
15.
Zurück zum Zitat Baron RH, Fey JV, Borgen PI et al (2007) Eighteen sensations after breast cancer surgery: a 5-year comparison of sentinel lymph node biopsy and axillary lymph node dissection. Ann Surg Oncol 14(5):1653–1661PubMedCrossRef Baron RH, Fey JV, Borgen PI et al (2007) Eighteen sensations after breast cancer surgery: a 5-year comparison of sentinel lymph node biopsy and axillary lymph node dissection. Ann Surg Oncol 14(5):1653–1661PubMedCrossRef
16.
Zurück zum Zitat Haid A, Kuehn T, Konstantiniuk P, Koberle-Wuhrer R, Knauer M, Kreienberg R, Zimmermann G (2002) Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol 28(7):705–710. doi:10.1053/ejso.2002.1327 PubMedCrossRef Haid A, Kuehn T, Konstantiniuk P, Koberle-Wuhrer R, Knauer M, Kreienberg R, Zimmermann G (2002) Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol 28(7):705–710. doi:10.​1053/​ejso.​2002.​1327 PubMedCrossRef
17.
Zurück zum Zitat Golshan M, Martin WJ, Dowlatshahi K (2003) Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection. Am Surg 69(3):209–211 discussion 212PubMed Golshan M, Martin WJ, Dowlatshahi K (2003) Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection. Am Surg 69(3):209–211 discussion 212PubMed
18.
Zurück zum Zitat Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, Kissin M, Mansel RE (2006) Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 95(3):279–293. doi:10.1007/s10549-005-9025-7 PubMedCrossRef Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, Kissin M, Mansel RE (2006) Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 95(3):279–293. doi:10.​1007/​s10549-005-9025-7 PubMedCrossRef
19.
Zurück zum Zitat Temple LK, Baron R, Cody HS III, Fey JV, Thaler HT, Borgen PI, Heerdt AS, Montgomery LL, Petrek JA, Van Zee KJ (2002) Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol 9(7):654–662PubMedCrossRef Temple LK, Baron R, Cody HS III, Fey JV, Thaler HT, Borgen PI, Heerdt AS, Montgomery LL, Petrek JA, Van Zee KJ (2002) Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol 9(7):654–662PubMedCrossRef
21.
Zurück zum Zitat Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98(9):599–609. doi:10.1093/jnci/djj158 PubMedCrossRef Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98(9):599–609. doi:10.​1093/​jnci/​djj158 PubMedCrossRef
22.
Zurück zum Zitat Langer I, Guller U, Berclaz G, Koechli OR, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M (2007) Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg 245(3):452–461. doi:10.1097/01.sla.0000245472.47748.ec PubMedCrossRef Langer I, Guller U, Berclaz G, Koechli OR, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M (2007) Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg 245(3):452–461. doi:10.​1097/​01.​sla.​0000245472.​47748.​ec PubMedCrossRef
23.
Zurück zum Zitat McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. doi:10.1200/JCO.2008.16.3725 McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. doi:10.​1200/​JCO.​2008.​16.​3725
24.
Zurück zum Zitat Rietman JS, Geertzen JH, Hoekstra HJ, Baas P, Dolsma WV, de Vries J, Groothoff JW, Eisma WH, Dijkstra PU (2006) Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer. Eur J Surg Oncol 32(2):148–152. doi:10.1016/j.ejso.2005.11.008 PubMedCrossRef Rietman JS, Geertzen JH, Hoekstra HJ, Baas P, Dolsma WV, de Vries J, Groothoff JW, Eisma WH, Dijkstra PU (2006) Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer. Eur J Surg Oncol 32(2):148–152. doi:10.​1016/​j.​ejso.​2005.​11.​008 PubMedCrossRef
25.
Zurück zum Zitat Schulze T, Mucke J, Markwardt J, Schlag PM, Bembenek A (2006) Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 93(2):109–119. doi:10.1002/jso.20406 PubMedCrossRef Schulze T, Mucke J, Markwardt J, Schlag PM, Bembenek A (2006) Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 93(2):109–119. doi:10.​1002/​jso.​20406 PubMedCrossRef
26.
Zurück zum Zitat Cormier JN, Xing Y, Zaniletti I, Askew RL, Stewart BR, Armer JM (2009) Minimal limb volume change has a significant impact on breast cancer survivors. Lymphology 42(4):161–175PubMed Cormier JN, Xing Y, Zaniletti I, Askew RL, Stewart BR, Armer JM (2009) Minimal limb volume change has a significant impact on breast cancer survivors. Lymphology 42(4):161–175PubMed
27.
Zurück zum Zitat Armer JM, Radina ME, Porock D, Culbertson SD (2003) Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 52(6):370–379PubMedCrossRef Armer JM, Radina ME, Porock D, Culbertson SD (2003) Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 52(6):370–379PubMedCrossRef
29.
Zurück zum Zitat Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR (2008) Lymphedema and quality of life in breast cancer survivors: the Iowa Women‘s Health Study. J Clin Oncol. doi:10.1200/JCO.2008.16.4731 Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR (2008) Lymphedema and quality of life in breast cancer survivors: the Iowa Women‘s Health Study. J Clin Oncol. doi:10.​1200/​JCO.​2008.​16.​4731
31.
Zurück zum Zitat Jager G, Doller W, Roth R (2006) Quality-of-life and body image impairments in patients with lymphedema. Lymphology 39(4):193–200PubMed Jager G, Doller W, Roth R (2006) Quality-of-life and body image impairments in patients with lymphedema. Lymphology 39(4):193–200PubMed
32.
Zurück zum Zitat Ancukiewicz M, Russell TA, Otoole J, Specht M, Singer M, Kelada A, Murphy CD, Pogachar J, Gioioso V, Patel M, Skolny M, Smith BL, Taghian AG (2011) Standardized method for quantification of developing lymphedema in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 79(5):1436–1443. doi:10.1016/j.ijrobp.2010.01.001 PubMedCrossRef Ancukiewicz M, Russell TA, Otoole J, Specht M, Singer M, Kelada A, Murphy CD, Pogachar J, Gioioso V, Patel M, Skolny M, Smith BL, Taghian AG (2011) Standardized method for quantification of developing lymphedema in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 79(5):1436–1443. doi:10.​1016/​j.​ijrobp.​2010.​01.​001 PubMedCrossRef
33.
Zurück zum Zitat Mahamaneerat WK, Shyu CR, Stewart BR, Armer JM (2008) Breast cancer treatment, BMI, post-op swelling/lymphoedema. J Lymphoedema 3(2):38–44PubMed Mahamaneerat WK, Shyu CR, Stewart BR, Armer JM (2008) Breast cancer treatment, BMI, post-op swelling/lymphoedema. J Lymphoedema 3(2):38–44PubMed
34.
Zurück zum Zitat Armer JM, Stewart BR, Shook RP (2009) 30-month post-breast cancer treatment lymphoedema. J Lymphoedema 4(1):14–18PubMed Armer JM, Stewart BR, Shook RP (2009) 30-month post-breast cancer treatment lymphoedema. J Lymphoedema 4(1):14–18PubMed
35.
Zurück zum Zitat Solway S, Beaton DE, McConnell S, Bombardier C (2002) The DASH outcome measure user‘s manual, 2nd edn. Institute for Work and Health, Toronto Solway S, Beaton DE, McConnell S, Bombardier C (2002) The DASH outcome measure user‘s manual, 2nd edn. Institute for Work and Health, Toronto
36.
Zurück zum Zitat Lee TS, Kilbreath SL, Sullivan G, Refshauge KM, Beith JM (2007) The development of an arm activity survey for breast cancer survivors using the Protection Motivation Theory. BMC Cancer 7:75. doi:10.1186/1471-2407-7-75 PubMedCrossRef Lee TS, Kilbreath SL, Sullivan G, Refshauge KM, Beith JM (2007) The development of an arm activity survey for breast cancer survivors using the Protection Motivation Theory. BMC Cancer 7:75. doi:10.​1186/​1471-2407-7-75 PubMedCrossRef
37.
Zurück zum Zitat Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 15(3):974–986PubMed Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 15(3):974–986PubMed
39.
Zurück zum Zitat Hack TF, Cohen L, Katz J, Robson LS, Goss P (1999) Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 17(1):143–149PubMed Hack TF, Cohen L, Katz J, Robson LS, Goss P (1999) Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 17(1):143–149PubMed
40.
Zurück zum Zitat Kiluk JV, Santillan AA, Kaur P, Laronga C, Meade T, Ramos D, Cox CE (2008) Feasibility of sentinel lymph node biopsy through an inframammary incision for a nipple-sparing mastectomy. Ann Surg Oncol 15(12):3402–3406. doi:10.1245/s10434-008-0156-z PubMedCrossRef Kiluk JV, Santillan AA, Kaur P, Laronga C, Meade T, Ramos D, Cox CE (2008) Feasibility of sentinel lymph node biopsy through an inframammary incision for a nipple-sparing mastectomy. Ann Surg Oncol 15(12):3402–3406. doi:10.​1245/​s10434-008-0156-z PubMedCrossRef
41.
Zurück zum Zitat Baron RH, Fey JV, Raboy S, Thaler HT, Borgen PI, Temple LK, Van Zee KJ (2002) Eighteen sensations after breast cancer surgery: a comparison of sentinel lymph node biopsy and axillary lymph node dissection. Oncol Nurs Forum 29(4):651–659. doi:10.1188/02.ONF.651-659 PubMedCrossRef Baron RH, Fey JV, Raboy S, Thaler HT, Borgen PI, Temple LK, Van Zee KJ (2002) Eighteen sensations after breast cancer surgery: a comparison of sentinel lymph node biopsy and axillary lymph node dissection. Oncol Nurs Forum 29(4):651–659. doi:10.​1188/​02.​ONF.​651-659 PubMedCrossRef
42.
Zurück zum Zitat Land SR, Kopec JA, Julian TB, Brown AM, Anderson SJ, Krag DN, Christian NJ, Costantino JP, Wolmark N, Ganz PA (2010) Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: national surgical adjuvant breast and bowel project phase III protocol B-32. J Clin Oncol 28(25):3929–3936. doi:10.1200/JCO.2010.28.2491 PubMedCrossRef Land SR, Kopec JA, Julian TB, Brown AM, Anderson SJ, Krag DN, Christian NJ, Costantino JP, Wolmark N, Ganz PA (2010) Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: national surgical adjuvant breast and bowel project phase III protocol B-32. J Clin Oncol 28(25):3929–3936. doi:10.​1200/​JCO.​2010.​28.​2491 PubMedCrossRef
43.
Zurück zum Zitat Leidenius M, Leivonen M, Vironen J, von Smitten K (2005) The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol 92(1):23–31. doi:10.1002/jso.20373 PubMedCrossRef Leidenius M, Leivonen M, Vironen J, von Smitten K (2005) The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol 92(1):23–31. doi:10.​1002/​jso.​20373 PubMedCrossRef
44.
Zurück zum Zitat Soran A, Falk J, Bonaventura M, Keenan D, Ahrendt G, Johnson R (2007) Is routine sentinel lymph node biopsy indicated in women undergoing contralateral prophylactic mastectomy? Magee-Womens Hospital experience. Ann Surg Oncol 14(2):646–651. doi:10.1245/s10434-006-9264-9 PubMedCrossRef Soran A, Falk J, Bonaventura M, Keenan D, Ahrendt G, Johnson R (2007) Is routine sentinel lymph node biopsy indicated in women undergoing contralateral prophylactic mastectomy? Magee-Womens Hospital experience. Ann Surg Oncol 14(2):646–651. doi:10.​1245/​s10434-006-9264-9 PubMedCrossRef
45.
Zurück zum Zitat Boughey JC, Cormier JN, Xing Y, Hunt KK, Meric-Bernstam F, Babiera GV, Ross MI, Kuerer HM, Singletary SE, Bedrosian I (2007) Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer 110(11):2542–2550. doi:10.1002/cncr.23067 PubMedCrossRef Boughey JC, Cormier JN, Xing Y, Hunt KK, Meric-Bernstam F, Babiera GV, Ross MI, Kuerer HM, Singletary SE, Bedrosian I (2007) Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer 110(11):2542–2550. doi:10.​1002/​cncr.​23067 PubMedCrossRef
48.
Zurück zum Zitat Black D, Specht M, Lee JM, Dominguez F, Gadd M, Hughes K, Rafferty E, Smith B (2007) Detecting occult malignancy in prophylactic mastectomy: preoperative MRI versus sentinel lymph node biopsy. Ann Surg Oncol 14(9):2477–2484. doi:10.1245/s10434-007-9356-1 PubMedCrossRef Black D, Specht M, Lee JM, Dominguez F, Gadd M, Hughes K, Rafferty E, Smith B (2007) Detecting occult malignancy in prophylactic mastectomy: preoperative MRI versus sentinel lymph node biopsy. Ann Surg Oncol 14(9):2477–2484. doi:10.​1245/​s10434-007-9356-1 PubMedCrossRef
49.
Zurück zum Zitat Perre CI, Hoefnagel CA, Kroon BB, Zoetmulder FA, Rutgers EJ (1996) Altered lymphatic drainage after lymphadenectomy or radiotherapy of the axilla in patients with breast cancer. Br J Surg 83(9):1258PubMedCrossRef Perre CI, Hoefnagel CA, Kroon BB, Zoetmulder FA, Rutgers EJ (1996) Altered lymphatic drainage after lymphadenectomy or radiotherapy of the axilla in patients with breast cancer. Br J Surg 83(9):1258PubMedCrossRef
Metadaten
Titel
Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery
verfasst von
Cynthia L. Miller
Michelle C. Specht
Melissa N. Skolny
Lauren S. Jammallo
Nora Horick
Jean O’Toole
Suzanne B. Coopey
Kevin Hughes
Michele Gadd
Barbara L. Smith
Alphonse G. Taghian
Publikationsdatum
01.10.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2231-1

Weitere Artikel der Ausgabe 3/2012

Breast Cancer Research and Treatment 3/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.